In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Inspire Medical Systems, Inc. stands tenth among them. Inspire Medical Systems, Inc. (NYSE:INSP), a leader in minimally invasive devices for obstructive sleep apnea (OSA), reported challenges in the commercial rollout of its new Inspire V system. Delays in onboarding treatment centers and navigating reimbursement processes have slowed full patient adoption, with some patients still using the older Inspire I ...

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc. (collectively, “Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that it has filed a lawsuit against Inspire Medical Systems, Inc. (“Inspire”) alleging that the Inspire IV and Inspire V de ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Inspire Medical Systems, Inc. for possible violations of federal securities laws and unlawful business practices following a significant reduction in the company's earnings guidance for fiscal 2025 [1][3]. Financial Performance - On August 5, 2025, Inspire reported better-than-expected second quarter results but drastically cut its full-year earnings guidance from $2.20 - $2.30 to $0.40 - $0.50, and revenue expectations from $940 million - $955 million to $900 million - $910 million [3]. - The company attributed the guidance reduction to challenges in the rollout of Inspire V, including training and onboarding issues, customer delays, and technical Medicare adoption delays [3]. Stock Market Reaction - Following the announcement of the revised guidance, Inspire's stock price dropped by $46.44, opening at $83.51 per share [4].